ArticleTherapeutic advances in respiratory disease
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Trial
- Biologic Switching in Patients with Severe Asthma: Effects on Exacerbations, Corticosteroid Use and Lung Function.Journal of clinical medicine · 2026Article
- Choosing and switching biologics for patients with severe asthma: Real-world data from the German Asthma Net (GAN).Allergologie select · 2026Article
- Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study.BMC pulmonary medicine · 2025Article
- Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab.Allergy · 2025Article
- Effectiveness of anti-IL-5/5Rα biologics in severe asthma in real-world studies: a systematic review and meta-analysis.ERJ open research · 2025Article
- Monoclonal Antibody Switching in Biologic Treatment of Chronic Rhinosinusitis with Nasal Polyps.Journal of clinical medicine · 2024Article
- Advancing Care in Severe Asthma: The Art of Switching Biologics.Advances in respiratory medicine · 2024Review
- Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period.Journal of asthma and allergy · 2024Article
- Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.International journal of molecular sciences · 2023Review
- Unanswered questions on the use of biologics in pediatric asthma.The World Allergy Organization journal · 2023Review
- Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.Journal of clinical medicine · 2023Article
- Switching Biological Therapies in Severe Asthma.International journal of molecular sciences · 2023Review
- Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023Article
- Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study.ERJ open research · 2022Article
- Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.Journal of personalized medicine · 2022Review
- Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA).ClinicoEconomics and outcomes research : CEOR · 2022Article
- Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.Journal of asthma and allergy · 2022Article
- Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy.Journal of asthma and allergy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice.
methodsA total of 41 consecutive patients with severe, persistent allergic, eosinophilic asthma, uncontrolled despite treatment with omalizumab, were enrolled in seven certified Clinical Respiratory Units of Southern Italy (Catania, Catanzaro, Foggia, Bari, Palermo, and two University Respiratory Units of Naples) and shifted to mepolizumab without a wash-out period. Data at baseline, after at least 12 months of therapy with omalizumab, and after at least 12 months of treatment with mepolizumab were collected.
resultsAfter at least 12 months of therapy with mepolizumab, patients experienced a significant decrease in the number of exacerbations/year (5.8 ± 1.8
conclusionResults of our real-life multicentric experience confirms that the shift to mepolizumab could be a good therapeutic strategy in severe eosinophilic allergic asthma not previously controlled by omalizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.